Florio AA, Ferlay J, Znaor A, Ruggieri D, Alvarez CS, Laversanne
M, Bray F, McGlynn KA, Petrick JL (2020) Global trends in
intrahepatic and extrahepatic cholangiocarcinoma incidence from
1993 to 2012. Cancer 126:2666–2678
2. Vital Statistics Japan (Ministry of Health, Labour and Welfare).
https://www.mhlw.go.jp/english/database/db-hw/vs01.html.
Accessed May 2020
3. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A,
Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP,
Roughton M, Bridgewater J (2010) Cisplatin plus gemcitabine versus
gemcitabine for biliary tract cancer. N Engl J Med 362:1273–1281
4. Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi
A, Nagino M, Kondo S, Nagaoka S, Funai J, Koshiji M, Nambu Y,
Furuse J, Miyazaki M, Nimura Y (2010) Gemcitabine alone or in
combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer 103:469–474
5. Miyazaki M, Yoshitomi H, Miyakawa S, Uesaka K, Unno M, Endo
I, Ota T, Ohtsuka M, Kinoshita H, Shimada K, Shimizu H, Tabata
M, Chijiiwa K, Nagino M, Hirano S, Wakai T, Wada K, Iasayama
H, Okusaka T, Tsuyuguchi T, Fujita N, Furuse J, Yamao K,
16.
1.
17.
18.
Murakami K, Yamazaki H, Kijima H, Nakanuma Y, Yoshida M,
Takayashiki T, Takada T (2015) Clinical practice guidelines for the
management of biliary tract cancers 2015: the 2nd English edition. J
Hepatobiliary Pancreat Sci 22:249–273
NCCN Clinical Practice Guidelines in Oncology Version 4, 2020.
Hepatobiliary cancers. https://www.nccn.org/professionals/
physician_gls/pdf/hepatobiliary.pdf. Accessed May 2020
Lamarca A, Palmer DH, Wasan H, et al. ABC-06|A randomized
phase III, multi-centre, open-label study of active symptom control
(ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC +
mFOLFOX) for patients(pts) with locally advanced / metastatic
biliary tract cancers (ABC) previously-treated with cisplatin/
gemcitabine (CisGem) chemotherapy. 2019 ASCO Annual
Meeting, (Abstract #4003)
Furuse J, Okusaka T, Boku N, Ohkawa S, Sawaki A, Masumoto T,
Funakoshi A (2008) S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II
study. Cancer Chemother Pharmacol 62:849–855
Suzuki E, Ikeda M, Okusaka T, Nakamori S, Ohkawa S, Nagakawa
T, Boku N, Yanagimoto H, Sato T, Furuse J (2013) A multicenter
phase II study of S-1 for gemcitabine-refractory biliary tract cancer.
Cancer Chemother Pharmacol 71:1141–1146
Sasaki T, Isayama H, Nakai Y et al (2013) Multicenter phase II
study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine. Investig
New Drugs 30:708–713
Kobayashi S, Ueno M, Ohkawa S, Andou T, Kameda R,
Yamamoto N, Morinaga S (2012) A retrospective study of S-1
monotherapy as second-line treatment for patients with advanced
biliary tract cancer. Jpn J Clin Oncol 42:800–806
Sasaki T, Isayama H, Yashima Y, Yagioka H, Kogure H, Arizumi
T, Togawa O, Matsubara S, Ito Y, Nakai Y, Sasahira N, Hirano K,
Tsujino T, Tada M, Kawabe T, Omata M (2009) S-1 monotherapy
in patients with advanced biliary tract cancer. Oncology 77:71–74
Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48:452–458
Eckel F, Schmid RM (2007) Chemotherapy in advanced biliary tract
carcinoma: a pooled analysis of clinical trials. Br J Cancer 96:896–902
Yonemoto N, Furuse J, Okusaka T, Yamao K, Funakoshi A, Ohkawa
S, Boku N, Tanaka K, Nagase M, Saisho H, Sato T (2007) A multicenter retrospective analysis of survival benefits of chemotherapy for
unresectable biliary tract cancer. Jpn J Clin Oncol 37:843–851
Sakai D, Kanai M, Kobayashi S et al (2018) Randomized phase III
study of gemcitabine, cisplatin plus S-1 (GCS) versus gemcitabine,
cisplatin (GC) for advanced biliary tract cancer (KHBO1401MITSUBA). Ann Oncol 29:viii205
Morizane C, Okusaka T, Mizusawa J, Katayama H, Ueno M, Ikeda M,
Ozaka M, Okano N, Sugimori K, Fukutomi A, Hara H, Mizuno N,
Yanagimoto H, Wada K, Tobimatsu K, Yane K, Nakamori S,
Yamaguchi H, Asagi A, Yukisawa S, Kojima Y, Kawabe K,
Kawamoto Y, Sugimoto R, Iwai T, Nakamura K, Miyakawa H,
Yamashita T, Hosokawa A, Ioka T, Kato N, Shioji K, Shimizu K,
Nakagohri T, Kamata K, Ishii H, Furuse J, members of the
Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical
Oncology Group (JCOG-HBPOG) (2019) Combination gemcitabine
plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III
clinical trial. Ann Oncol 30:1950–1958
Tella SH, Kommalapati A, Borad MJ, Mahipal A (2020) Second-line
therapies in advanced biliary tract cancers. Lancet Oncol 21:e29–e41
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
...
論文の公開元へ
